Home

- Leukemia
  - Lymphocytic
    - R/R CD19+ precursor B-lymphoblastic leukemia
      - ▼ **10030:** A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA -4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
    - CD3+ acute lymphoma, or poor-risk chronic subtypes of adult t-cell lymphoma/leukemia
      - **10335:** A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
  - Myelogenous
    - R/R AML, myelodysplastic syndrome, or chronic myelomonocytic leukemia
      - ▼ **10246:** A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
      - **10273:** A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia
      - **10264:** The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
      - **10434**: Randomized Phase 2 Study of CPX-351 + Pomalidomide versus CPX-351 in Newly Diagnosed AML with MDS-Related Changes
      - **10237:** A Phase 1 Study of MLN7243 (TAK-243) for Either Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia Refractory to Hypomethylating Agents
      - **10538:** Venetoclax In Combination with ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial
    - AML with wild-type p53 (R/R or front line)
      - **10075:** A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia
      - **10367:** A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML)
    - Mutated AML
      - **10417**: Clinical Evaluation of ASTX727 in Combination with Venetoclax All-Oral Therapy vs Standard of Care Cytarabine and Anthracycline Induction Chemotherapy for Younger FLT3WT Patients with ELN High- Risk Acute Myeloid Leukemia
      - ***10596:** A Phase 1b Study of Menin Inhibitor SNDX-5613 with Daunorubicin and Cytarabine in Newly Diagnosed Patients with Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL Rearranged Disease
    - AML (front line therapy)
      - **10300:** BLAST MRD AML-1: A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia
      - **10334:** BLAST MRD AML-2: A Randomized Phase 2 Study of Venetoclax, Azacitadine, and Pembrolizumab Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia Who Are Ineligible or Who Refuse Intensive Chemotherapy
  - Hematologic malignancy
    - Hematologic malignancy, not otherwise stated
      - **10014:** A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: November 10, 2022